Amyloid heart disease module 2: management

Released6 April 2021     Expires: 06 April 2023      Programme: Amyloid heart disease 1 CPD/CME credit

Sponsorship Statement: These BJC learning modules have been supported by Pfizer with an independent medical education grant.

Learning objectives

Upon completing this module, healthcare professionals should know more about:

  • How to manage transthyretin amyloidosis
  • The comprehensive approach to supportive care in order to preserve organ function
  • Treatments to reduce transthretin (TTR) in the plasma, and stabilise the tetramic structure of TTR

Advertisement
Heart failure - BJC Learning programme
For healthcare professionals only

Faculty

Tamer Rezk, NIHR Clinical Lecturer UCL Division of Medicine, National Amyloidosis Centre, Division of Medicine, University College London
Julian D Gillmore, Professor, Head of Centre, National Amyloidosis Centre, Division of Medicine, University College London

Accreditation

1 CPD/CME credit, 1.0 hour
BJC Learning has assigned one hour of CPD/CME credit to this module

To make the “Take test” button available – please click the “Module content” button first.

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

8 thoughts on “Amyloid heart disease module 2: management”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.